

1

2 **Title page:**

3 Complete manuscript title: **Acute monocular oligemia in a patient with migraine with**  
4 **aura demonstrated using OCT-angiography: a case report.**

5 Type of article: *Case report.*

6 **Author names**

7 Julio González-Martín-Moro <sup>1,2</sup> (MD, PhD)

8 Jesús Porta Etesam<sup>3</sup>

9 Belén Pilo de la Fuente<sup>4</sup>(MD, PhD)

10 Irene Fuentes Vega <sup>1</sup> (Optometrist)

11 Inés Contreras<sup>5,6</sup>(MD, PhD)

12 (1)Ophthalmology Department; University Hospital of Henares. Madrid. Spain

13 (2)Department of Medicine. University Francisco de Vitoria. Madrid. Spain

14 (3)Neurology Department. Clínico San Carlos University Hospital. Madrid. Spain

15 (4)Neurology Department. Getafe University Hospital. Madrid. Spain

16 (5)Ophthalmology Department; University Hospital Ramón y Cajal. Madrid. Spain

17 (6)Clínica Rementería. Madrid. Spain

18

19

20 Corresponding author:

21 Julio González Martín-Moro

22 Postal address: Av. Marie Curie sn. Coslada. 28820. Madrid. Spain

23 [juliogmm@yahoo.es](mailto:juliogmm@yahoo.es); [juliogazpeitia@gmail.com](mailto:juliogazpeitia@gmail.com)

24 Tel: +34 659 912578

25

26 **Declarations**

27 Conflict of interest: The authors declare that there is no conflict of interest.

28 Consent for publication: Written informed consent from the patient was obtained for  
29 the publication of this case report and the images.

30 Funding: This research received no specific grant from any funding agency.

31

32

33

34

35

36

37

38

39

40

41 **Acute monocular oligemia in a patient with migraine with aura**  
42 **demonstrated using OCT-angiography: a case report.**

43 **Abstract**

44 **Introduction**

45 Migraine is one of the most common causes of transient visual loss. Optical coherence  
46 tomography angiography (OCTA) provides fast and non-invasive imaging of the retinal  
47 vessels. We report the first case of monocular retinal oligemia demonstrated using  
48 OCTA during a migraine attack with aura.

49 **Case description**

50 A 27-year-old man with a previous history of migraine with visual aura was seen in the  
51 emergency room due to acute left hemicranial pain with positive visual symptoms in  
52 his right eye. The patient reported a blue stain in his right eye. Optical coherence  
53 tomography angiography (OCT-A) showed an extensive area of hypoperfusion in the  
54 macular region of his right eye. Forty-eight hours later visual symptoms had improved  
55 and the OCT-A showed a significant reduction in the area of hypoperfusion. Seven days  
56 later the patient was asymptomatic and retinal perfusion had returned to normal  
57 values.

58 **Conclusion**

59 Monocular involvement suggests that these retinal vascular changes are independent  
60 from cerebral vascular changes, supporting the hypothesis of selective retinal ganglion  
61 cell layer spreading depression as the possible cause of some cases of retinal migraine.

62 **Keywords:** retinal migraine, OCTA, retina, ischemia, retinal ganglion cell layer, cortical  
63 spreading depression, case report.

## 64 **Introduction**

65 Migraine affects approximately 15% of the global population. It is the most prevalent  
66 neurological condition and the third most frequent global health disorder in both  
67 genders<sup>1</sup>. Migraine is also one of the most common causes of transient visual loss <sup>2</sup>.  
68 Visual field loss and positive visual symptoms are usually homonymous; nevertheless,  
69 some patients develop monocular visual symptoms. The terminology used in these  
70 monocular cases has been confusing, but nowadays retinal migraine is the accepted  
71 term by the HIS 3 classification<sup>3</sup>.

72 From a physiological point of view, retinal migraine is thought to be a neuro-vascular  
73 phenomenon, in which cortical spreading depression seems to be the main  
74 mechanism, with vascular changes as a secondary phenomenon<sup>4</sup>. Non-arteritic  
75 ischemic optic neuropathies and arterial vascular occlusions have been reported in  
76 patients with migraine and there is evidence of vasospasm of the retinal arteries  
77 occurring in some patients<sup>5, 6</sup>.

78 These episodes of ocular ischemia may explain why structural changes in the optic  
79 nerve and retina have been consistently reported in populations that suffer from  
80 migraines. Several studies have shown that there is a decrease in the retinal nerve  
81 fiber layer, with more severe changes in patients that suffer migraine with aura than in  
82 those without aura<sup>1</sup>.

83 Optical coherence tomography (OCT) was invented in 1991 and has evolved  
84 tremendously since then. Traditionally, fluorescein angiography was used to evaluate  
85 the retinal vasculature. However, nowadays OCT angiography (OCTA) provides fast and  
86 non-invasive imaging of the retinal vessels. Although fluorescein angiography is still  
87 used in certain cases <sup>7</sup>, it has been largely displaced by OCTA.

88

## 89 **Case description**

90 We report the case of a 27-year-old, right-handed man who suffered from recurrent  
91 headaches since he was 14 which fulfilled HIS III criteria for migraine with aura. A CT  
92 scan performed when he was seventeen was normal. He had a family history of  
93 migraine with aura. The episode for which he consulted had begun 48 hours earlier as  
94 a typical episode of migraine with aura with left hemicranial pain and flashes in the  
95 contralateral eye. Forty-eight hours later he perceived a bluish stain in the center of his  
96 right eye, that spread gradually . The headache was similar to those he had suffered  
97 periodically. He referred a non-pulsatile pain in the left side of the head, without  
98 nausea and vomiting. He also had photophobia and sonophobia but not osmophobia.  
99 The patient was under treatment with Tryptizol and had taken Naproxen at home.  
100 Neurological examination was normal and the neuroophthalmological evaluation  
101 showed a decimal uncorrected visual acuity of 0.9 in both eyes. Intraocular pressure,  
102 pupil examination and ocular fundus were normal, but optical coherence tomography  
103 angiography (OCT-A) performed with OCT Triton, Topcon, Tokyo, revealed the  
104 presence of an extensive area of hypoperfusion in his right retina. These changes were  
105 more severe in the superficial retinal plexus than in the deep retinal plexus (Figure 1).

106 Macular OCT showed normal foveal profiles without edema in any of the retinal layers,  
107 and normal ganglion cell layer thickness. Optic disc OCT was not performed during the  
108 acute phase, but was carried out on the one-year follow-up consultation and did not  
109 show any abnormalities (peripapillary retinal nerve fiber layer average thickness was  
110 112 microns in his RE and 109 microns in his LE) Despite the presence of this area of  
111 oligemia, central visual fields were normal in both eyes. He was treated with  
112 intravenous Metamizol, which reduced the pain. Forty-eight hours later, only mild pain  
113 persisted in the left side of his head and the bluish stain was very small and limited to  
114 the superotemporal area, next to center of the visual field. OCTA showed normal  
115 retinal vasculature (Figure 2). Eight days later the patient was asymptomatic and OCTA  
116 remained normal. Cerebral magnetic resonance imaging performed one month later  
117 did not reveal any abnormalities.

## 118 **Conclusion**

119 The development of new technologies reshapes our way of thinking. For example, OCT  
120 technology has allowed us to measure the retinal ganglion cell layer, showing that  
121 occipital lesions can induce anterograde degeneration of these cells. This finding has  
122 proven that the paradigm that stated that retrograde trans-synaptic neuronal  
123 degeneration did not take place in the human brain was wrong<sup>8</sup>.

124 A decade ago, in an editorial, Winterkorn reported that vasospasm during a migraine  
125 attack had been photographically documented in fewer than 10 patients<sup>9</sup>. However  
126 fundus photography can only detect vasospasm in the main retinal arterioles and most  
127 cases of hypoperfusion are probably caused by changes in neuronal activity and  
128 platelet function, not by vasospasm.<sup>9</sup> OCTA can detect hypoperfusion in smaller

129 vessels and thereby constitutes a much more sensitive method to detect retinal  
130 oligemia. In a recent article, Atilla et al reported reversible bilateral retinal  
131 hypoperfusion in the macular area in one patient with migraine.<sup>10</sup>

132 Our case is not easy to understand from a topographical point of view, since the retinal  
133 changes were monocular and contralateral to the headache. They may be related  
134 processes but they do not seem to respond to the same migraine phase  
135 pathophysiology. The oligemia could be the consequence of a primary retinal  
136 spreading depression phenomena, similar to classic aura. In our patient, retinal  
137 oligemia was more severe in the superficial retinal plexus and therefore it might have  
138 been due to selective spreading depression of the retinal ganglion cell layer (Figure 1).  
139 This might explain why it was contralateral to the headache as well as the absence of a  
140 retinal lesion after the resolution of the retinal aura (Figure 2). There is one other  
141 report of OCTA performed during a migraine attack. In this case, oligemia affected  
142 both retinas, and the severity of vascular changes was similar in the superficial and  
143 deep plexus<sup>10</sup>.

144 We conclude that OCTA allows fast and non-invasive measurements of ocular  
145 circulation and it is probably going to provide new insights into the pathophysiology of  
146 retinal migraine in the future, leading to better characterization and classification. In  
147 this patient, vascular changes were more severe in the superficial plexus, supporting  
148 the hypothesis of selective retinal ganglion cell layer spreading depression as the  
149 possible cause of some cases of retinal migraine. Nevertheless, this idea of selective  
150 retinal ganglion cell layer spreading depression as the cause of some cases of  
151 monocular should be confirmed in the future by more extensive case report series.

152

153 **Declarations**

154 Conflict of interest: The authors declare that there is no conflict of interest.

155 Consent for publication: Written informed consent from the patient was obtained for  
156 the publication of this case report and the images.

157 Funding: This research received no specific grant from any funding agency.

158

159

160

161

Reference List


162

- 163 1. Ascaso FJ, Marco S, Mateo J, Martínez M, Esteban O and Grzybowski A. Optical  
164 Coherence Tomography in Patients with Chronic Migraine: Literature Review and Update.  
165 *Frontiers in neurology*. 2017; 8: 684-.
- 166 2. Foroozan R. Visual dysfunction in migraine. *Int Ophthalmol Clin*. 2009; 49: 133-46.
- 167 3. [https://ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-](https://ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf)  
168 [Headache-Disorders-3rd-Edition-2018.pdf](https://ichd-3.org/wp-content/uploads/2018/01/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf).
- 169 4. Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. *Headache*. 2018;  
170 58 Suppl 1: 4-16.
- 171 5. Gonzalez-Martin-Moro J, Pilo-de-la-Fuente B and Moreno-Martin P. [Migraineous  
172 anterior optic ischemic neuropathy]. *Arch Soc Esp Oftalmol*. 2009; 84: 473-6.
- 173 6. Christakis PG, Alon R and Brent MH. Recurrent visual field defect associated with  
174 migraine resulting in a hemiretinal artery occlusion. *Canadian journal of ophthalmology*  
175 *Journal canadien d'ophtalmologie*. 2018; 53: e92-e4.
- 176 7. Littlewood R, Mollan SP, Pepper IM and Hickman SJ. The Utility of Fundus Fluorescein  
177 Angiography in Neuro-Ophthalmology. *Neuro-ophthalmology (Aeolus Press)*. 2019; 43: 217-34.
- 178 8. Keller J, Oakley JD, Russakoff DB, Andorra-Ingles M, Villoslada P and Sanchez-Dalmau  
179 BF. Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy.  
180 *Graefes Arch Clin Exp Ophthalmol*. 2016; 254: 561-7.
- 181 9. Winterkorn JMS. "Retinal Migraine" is an oxymoron. *Journal of neuro-ophthalmology :  
182 the official journal of the North American Neuro-Ophthalmology Society*. 2007; 27: 1-2.
- 183 10. Bingol Kiziltunc P and Atilla H. Vascular changes with optical coherence tomography  
184 angiography during aura of migraine: A case report. *Eur J Ophthalmol*. 2020:  
185 1120672119899900.


186




## Superficial plexus




## Deep plexus



## Photoreceptors




## Choriocapillaris



187

188

189 Figure 1. An extensive area of oligemia was present during the attack. It was more severe in  
190 the superficial plexus than in the deep plexus (red arrows). Figures show OCT-A maps of the  
191 retinal superficial plexus, retinal deep plexus, photoreceptor (in healthy people this level  
192 should be avascular) and choriocapillaris. RE=right eye, LE=left eye.



193

194 Figure 2. An extensive area of oligemia was present during the attack in the retina superficial  
195 plexus in the right eye. Forty-eight hours later the retinal plexus had returned to normal.

196 RE=right eye; LE=left eye.

197

198

199



CARE Checklist of information to include when writing a case report



Topic	Item	Checklist item description	Reported on Line
Title	1	The diagnosis or intervention of primary focus followed by the words "case report" . . . . .	40, 41
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report" . . . . .	60,61
Abstract (no references)	3a	Introduction: What is unique about this case and what does it add to the scientific literature? . . . . .	83-85
	3b	Main symptoms and/or important clinical findings . . . . .	88-109
	3c	The main diagnoses, therapeutic interventions, and outcomes . . . . .	88-109
	3d	Conclusion—What is the main "take-away" lesson(s) from this case? . . . . .	135-140
Introduction	4	One or two paragraphs summarizing why this case is unique (may include references) . . . . .	135-140
Patient Information	5a	De-identified patient specific information. . . . .	88-89
	5b	Primary concerns and symptoms of the patient. . . . .	91-97
	5c	Medical, family, and psycho-social history including relevant genetic information . . . . .	88-91
	5d	Relevant past interventions with outcomes . . . . .	94-97
Clinical Findings	6	Describe significant physical examination (PE) and important clinical findings. . . . .	98-109
Timeline	7	Historical and current information from this episode of care organized as a timeline . . . . .	88-109
Diagnostic Assessment	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys). . . . .	100-103; 109-110
	8b	Diagnostic challenges (such as access to testing, financial, or cultural) . . . . .	
	8c	Diagnosis (including other diagnoses considered) . . . . .	89
	8d	Prognosis (such as staging in oncology) where applicable . . . . .	
Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care) . . . . .	96-97
	9b	Administration of therapeutic intervention (such as dosage, strength, duration) . . . . .	96-97
	9c	Changes in therapeutic intervention (with rationale) . . . . .	96-97
Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available) . . . . .	106-108
	10b	Important follow-up diagnostic and other test results . . . . .	106-108
	10c	Intervention adherence and tolerability (How was this assessed?) . . . . .	96-97
	10d	Adverse and unanticipated events . . . . .	
Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report . . . . .	125-135
	11b	Discussion of the relevant medical literature with references. . . . .	112-124
	11c	The scientific rationale for any conclusions (including assessment of possible causes) . . . . .	136-141
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion . . . . .	136-141
Patient Perspective	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received . . . . .	
Informed Consent	13	Did the patient give informed consent? Please provide if requested . . . . .	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>

200

201

202